F R Hirsch

Summary

Affiliation: University of Colorado Health Sciences Center
Country: USA

Publications

  1. ncbi Increased epidermal growth factor receptor gene copy number detected by fluorescence in situ hybridization associates with increased sensitivity to gefitinib in patients with bronchioloalveolar carcinoma subtypes: a Southwest Oncology Group Study
    Fred R Hirsch
    University of Colorado Health Sciences Center, Denver, CO, USA
    J Clin Oncol 23:6838-45. 2005
  2. ncbi The role of genetic testing in the prediction of response to EGFR inhibitors in NSCLC
    F R Hirsch
    Department of Medical Oncology, University of Colorado Cancer Center, Aurora, CO 80045, USA
    Oncogene 28:S1-3. 2009
  3. ncbi Epidermal growth factor receptor in non-small-cell lung carcinomas: correlation between gene copy number and protein expression and impact on prognosis
    Fred R Hirsch
    Department of Pathology, University of Colorado Health Sciences Center, Denver, CO 80262, USA
    J Clin Oncol 21:3798-807. 2003
  4. ncbi Role of biomarkers for early detection of lung cancer and chemoprevention
    F R Hirsch
    Dept of Pathology, University of Colorado Health Sciences Centre, Denver 80262, USA
    Eur Respir J 19:1151-8. 2002
  5. ncbi IV international conference on prevention and early detection of lung cancer, Reykjavik, Iceland, August 9-12, 2001
    Fred R Hirsch
    Department of Medical Oncology/Pathology, University of Colorado Cancer Center, 4200 E. Ninth Avenue, B 188, Denver, CO 80262, USA
    Lung Cancer 37:325-44. 2002
  6. ncbi The prognostic and predictive role of histology in advanced non-small cell lung cancer: a literature review
    Fred R Hirsch
    University of Colorado Cancer Center, Aurora, Colorado 80045, USA
    J Thorac Oncol 3:1468-81. 2008
  7. ncbi Fluorescence in situ hybridization subgroup analysis of TRIBUTE, a phase III trial of erlotinib plus carboplatin and paclitaxel in non-small cell lung cancer
    Fred R Hirsch
    University of Colorado Cancer Center, Aurora, CO 80045, USA
    Clin Cancer Res 14:6317-23. 2008
  8. ncbi Epidermal growth factor family of receptors in preneoplasia and lung cancer: perspectives for targeted therapies
    Fred R Hirsch
    University of Colorado Cancer Center, Departments of Medicine Medical Oncology and Pathology, Denver, CO 80262, USA
    Lung Cancer 41:S29-42. 2003
  9. ncbi Increased EGFR gene copy number detected by fluorescent in situ hybridization predicts outcome in non-small-cell lung cancer patients treated with cetuximab and chemotherapy
    Fred R Hirsch
    Southwest Oncology Group, San Antonio, USA
    J Clin Oncol 26:3351-7. 2008
  10. ncbi First-generation epidermal growth factor receptor inhibitors in non-small cell lung cancer: clinical impact of the epidermal growth factor receptor fluorescence in situ hybridization assay
    Fred R Hirsch
    Division of Medical Oncology, University of Colorado, Health Sciences Center, Aurora, CO, USA
    J Thorac Oncol 3:S138-42. 2008

Detail Information

Publications100

  1. ncbi Increased epidermal growth factor receptor gene copy number detected by fluorescence in situ hybridization associates with increased sensitivity to gefitinib in patients with bronchioloalveolar carcinoma subtypes: a Southwest Oncology Group Study
    Fred R Hirsch
    University of Colorado Health Sciences Center, Denver, CO, USA
    J Clin Oncol 23:6838-45. 2005
    ..Epidermal growth factor receptor (EGFR) inhibitors demonstrated response rates of 20% to 30% in patients with advanced BAC subtypes, but selection methods for patient therapy are not established...
  2. ncbi The role of genetic testing in the prediction of response to EGFR inhibitors in NSCLC
    F R Hirsch
    Department of Medical Oncology, University of Colorado Cancer Center, Aurora, CO 80045, USA
    Oncogene 28:S1-3. 2009
    ..This supplement will review the current and emerging treatments for patients with advanced NSCLC and the molecular predictors of response that may facilitate the future clinical application of personalized medicine...
  3. ncbi Epidermal growth factor receptor in non-small-cell lung carcinomas: correlation between gene copy number and protein expression and impact on prognosis
    Fred R Hirsch
    Department of Pathology, University of Colorado Health Sciences Center, Denver, CO 80262, USA
    J Clin Oncol 21:3798-807. 2003
    ..The molecular mechanisms responsible for EGFR overexpression are poorly understood. Materials and..
  4. ncbi Role of biomarkers for early detection of lung cancer and chemoprevention
    F R Hirsch
    Dept of Pathology, University of Colorado Health Sciences Centre, Denver 80262, USA
    Eur Respir J 19:1151-8. 2002
    ....
  5. ncbi IV international conference on prevention and early detection of lung cancer, Reykjavik, Iceland, August 9-12, 2001
    Fred R Hirsch
    Department of Medical Oncology/Pathology, University of Colorado Cancer Center, 4200 E. Ninth Avenue, B 188, Denver, CO 80262, USA
    Lung Cancer 37:325-44. 2002
  6. ncbi The prognostic and predictive role of histology in advanced non-small cell lung cancer: a literature review
    Fred R Hirsch
    University of Colorado Cancer Center, Aurora, Colorado 80045, USA
    J Thorac Oncol 3:1468-81. 2008
    ..This review examined histology as a potential prognostic and/or predictive factor of clinical outcomes in advanced NSCLC...
  7. ncbi Fluorescence in situ hybridization subgroup analysis of TRIBUTE, a phase III trial of erlotinib plus carboplatin and paclitaxel in non-small cell lung cancer
    Fred R Hirsch
    University of Colorado Cancer Center, Aurora, CO 80045, USA
    Clin Cancer Res 14:6317-23. 2008
    ..Methods: EGFR FISH analysis was done using LSI EGFR SpectrumOrange/CEP7 SpectrumGreen probe...
  8. ncbi Epidermal growth factor family of receptors in preneoplasia and lung cancer: perspectives for targeted therapies
    Fred R Hirsch
    University of Colorado Cancer Center, Departments of Medicine Medical Oncology and Pathology, Denver, CO 80262, USA
    Lung Cancer 41:S29-42. 2003
    ..Gene amplification for EGFR and HER2 is demonstrated in only 5-10% of the tumors. The treatment status and therapeutic limitation with trastuzumab (Herceptin) in lung cancer compared to breast cancer is discussed...
  9. ncbi Increased EGFR gene copy number detected by fluorescent in situ hybridization predicts outcome in non-small-cell lung cancer patients treated with cetuximab and chemotherapy
    Fred R Hirsch
    Southwest Oncology Group, San Antonio, USA
    J Clin Oncol 26:3351-7. 2008
    ..Here, we evaluate EGFR FISH as a predictive marker in NSCLC patients receiving the EGFR monoclonal antibody inhibitor cetuximab plus chemotherapy...
  10. ncbi First-generation epidermal growth factor receptor inhibitors in non-small cell lung cancer: clinical impact of the epidermal growth factor receptor fluorescence in situ hybridization assay
    Fred R Hirsch
    Division of Medical Oncology, University of Colorado, Health Sciences Center, Aurora, CO, USA
    J Thorac Oncol 3:S138-42. 2008
    ....
  11. ncbi Epidermal growth factor receptor immunohistochemistry: comparison of antibodies and cutoff points to predict benefit from gefitinib in a phase 3 placebo-controlled study in advanced nonsmall-cell lung cancer
    Fred R Hirsch
    Division of Medical Oncology, University of Colorado Cancer Center, Aurora, CO 80045, USA
    Cancer 112:1114-21. 2008
    ..Two different antibodies, scoring systems, and cutoff points of epidermal growth factor receptor (EGFR) protein expression were compared to predict response and survival of enrolled patients...
  12. ncbi Advances in the biology of lung cancer chemoprevention
    Fred R Hirsch
    University of Colorado Cancer Center, 12801 E 17th Avenue, POB 6511, Mail 8111, Aurora, CO 80010, USA
    J Clin Oncol 23:3186-97. 2005
    ....
  13. ncbi Molecular predictors of outcome with gefitinib in a phase III placebo-controlled study in advanced non-small-cell lung cancer
    Fred R Hirsch
    University of Colorado Cancer Center, PO Box 6511, Mail Stop 8111, Aurora, CO 80045, USA
    J Clin Oncol 24:5034-42. 2006
    ..We analyzed ISEL tumor biopsy samples to examine relationships between biomarkers and clinical outcome after gefitinib treatment in a placebo-controlled setting...
  14. ncbi Biomarkers for prediction of sensitivity to EGFR inhibitors in non-small cell lung cancer
    Fred R Hirsch
    University of Colorado Cancer Center, Department of Medicine Medical Oncology and Pathology, Aurora, Colorado 80010, USA
    Curr Opin Oncol 17:118-22. 2005
    ..Objective response is achieved in 10 to 28% of the patients, and about 30% will achieve stable disease. A major problem is how to select the patients, who will benefit from treatment, and who will not...
  15. ncbi Evaluation of HER-2/neu gene amplification and protein expression in non-small cell lung carcinomas
    F R Hirsch
    Department of Pathology, Campus Box B216, University of Colorado Health Sciences Center, 4200 East 9th Avenue, Denver, Colorado, CO 80262, USA
    Br J Cancer 86:1449-56. 2002
    ..The therapeutic implications of protein expression and gene amplification in lung cancer need to be examined in prospective clinical trials...
  16. ncbi Predictive value of EGFR and HER2 overexpression in advanced non-small-cell lung cancer
    F R Hirsch
    Department of Medical Oncology, University of Colorado Cancer Center, Aurora, CO 80045, USA
    Oncogene 28:S32-7. 2009
    ..These considerations suggest that the simultaneous inhibition of EGFR and HER2 may warrant further study in patients with NSCLC...
  17. ncbi Early detection of lung cancer: clinical perspectives of recent advances in biology and radiology
    F R Hirsch
    Department of Medicine and Pathology University of Colorado Cancer Center Denver 80262, USA
    Clin Cancer Res 7:5-22. 2001
    ..The present article reviews the recent advances in the diagnosis of preinvasive and early-invasive cancer to identify biomarkers for early detection of lung cancer and for chemoprevention studies...
  18. ncbi Superiority of high-dose platinum (cisplatin and carboplatin) compared to carboplatin alone in combination chemotherapy for small-cell lung carcinoma: a prospective randomised trial of 280 consecutive patients
    F R Hirsch
    Rigshospitalet, Finsen Center, Department of Oncology, Denmark
    Ann Oncol 12:647-53. 2001
    ....
  19. ncbi Future developments in the treatment of lung cancer
    Fred R Hirsch
    Department of Medical Oncology Pathology, University of Colorado, Cancer Center, B 188, 4200 East Ninth Avenue, Denver, CO 80262, USA
    Lung Cancer 38:S81-5. 2002
    ..Together with developments of new technology available for early diagnosis new paradigms for management of lung cancer are under development with great promises for improvement of the overall prognosis...
  20. ncbi Expression of Her-2/neu in human lung cancer cell lines by immunohistochemistry and fluorescence in situ hybridization and its relationship to in vitro cytotoxicity by trastuzumab and chemotherapeutic agents
    P A Bunn
    Lung Cancer Program, Department of Medicine, University of Colorado Cancer Center, 4200 East Ninth Avenue, Denver CO 80262, USA
    Clin Cancer Res 7:3239-50. 2001
    ....
  21. ncbi Epidermal growth factor receptor gene copy number and protein level are not associated with outcome of non-small-cell lung cancer patients treated with chemotherapy
    R Dziadziuszko
    University of Colorado Health Sciences Center, Aurora, CO, USA
    Ann Oncol 18:447-52. 2007
    ..Clinical relevance of these features in patients treated with chemotherapy has not been reported...
  22. ncbi Epidermal growth factor receptor gene and protein and gefitinib sensitivity in non-small-cell lung cancer
    Federico Cappuzzo
    University of Colorado Health Sciences Center and University of Colorado Cancer Center, Aurora, CO 80010, USA
    J Natl Cancer Inst 97:643-55. 2005
    ..We carried out a clinical study to compare the relationship between EGFR gene copy number, EGFR protein expression, EGFR mutations, and Akt activation status as predictive markers for gefitinib therapy in advanced NSCLC...
  23. ncbi Insulin-like growth factor receptor 1 (IGFR-1) is significantly associated with longer survival in non-small-cell lung cancer patients treated with gefitinib
    F Cappuzzo
    University of Colorado Cancer Center, Department of Medicine/Medical Oncology and Pathology, Aurora, USA
    Ann Oncol 17:1120-7. 2006
    ..Clinical relevance of these two biomarkers as determinant for acquired resistance, and the prognostic role of IGFR-1 expression in patients not exposed to TKIs should be evaluated further...
  24. ncbi Combination of EGFR gene copy number and protein expression predicts outcome for advanced non-small-cell lung cancer patients treated with gefitinib
    F R Hirsch
    Division of Medical Oncology, Department of Medicine, University of Colorado Health Sciences Center and Cancer Center, Aurora, CO 80010, USA
    Ann Oncol 18:752-60. 2007
    ..Biological markers for optimal selection of patient to epidermal growth factor receptor (EGFR)-targeted therapies are not established in advanced non-small-cell lung cancer (NSCLC)...
  25. ncbi HER3 genomic gain and sensitivity to gefitinib in advanced non-small-cell lung cancer patients
    F Cappuzzo
    Department of Medicine Medical Oncology and Pathology, University of Colorado Cancer Center, Campus Box 8117 PO Box 6511, Aurora, CO 80045, USA
    Br J Cancer 93:1334-40. 2005
    ..Significantly different clinical end points were not observed between patients with HER3+/P-Akt+ and HER3- and/or P-Akt- tumours. Genomic gain for HER3 is not a marker for response or resistance to TKI therapy in advanced NSCLC patients...
  26. ncbi Analysis of c-ErbB1/epidermal growth factor receptor and c-ErbB2/HER-2 expression in bronchial dysplasia: evaluation of potential targets for chemoprevention of lung cancer
    Daniel T Merrick
    Department of Pathology, University of Colorado Cancer Center, Denver, Colorado, USA
    Clin Cancer Res 12:2281-8. 2006
    ..Molecular characterization of factors involved in controlling progression of bronchial dysplasias will provide markers of premalignant change and identify targets for chemoprevention...
  27. ncbi Antitumor activity of the epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor gefitinib (ZD1839, Iressa) in non-small cell lung cancer cell lines correlates with gene copy number and EGFR mutations but not EGFR protein levels
    Barbara A Helfrich
    Tobacco Related Malignancy Program, University of Colorado Cancer Center, Aurora, CO 80010, USA
    Clin Cancer Res 12:7117-25. 2006
    ..Several of these have subsequently been shown to identify NSCLC patients likely to benefit from gefitinib therapy...
  28. ncbi Outcome of combination chemotherapy in extensive stage small-cell lung cancer: any treatment related progress?
    U N Lassen
    Finsen Center, Department of Oncology, Rigshospitalet, Copenhagen, Denmark
    Lung Cancer 20:151-60. 1998
    ..No stage migration or treatment-related improved outcome was observed in extensive disease. We suggest restricting aggressive treatment to patients with favorable prognosis and long-term survival as a realistic aim...
  29. ncbi ErbB-3 expression is associated with E-cadherin and their coexpression restores response to gefitinib in non-small-cell lung cancer (NSCLC)
    S E Witta
    Department of Medicine Division of Medical Oncology, University of Colorado Health Sciences Center and University of Colorado Cancer Center, Aurora, CO 80010, USA
    Ann Oncol 20:689-95. 2009
    ..Here, we correlated the expressions of ErbB-3 and E-cadherin in NSCLC tumors and cell lines, their effect on response to gefitinib, and induction of both by the histone deacetylase (HDAC) inhibitors vorinostat and SNDX-275...
  30. ncbi Insulin-like growth factor receptor 1 (IGF1R) gene copy number is associated with survival in operable non-small-cell lung cancer: a comparison between IGF1R fluorescent in situ hybridization, protein expression, and mRNA expression
    Rafal Dziadziuszko
    University of Colorado Cancer Center, PO Box 6511, Mail Stop 8111, Aurora, CO 80045, USA
    J Clin Oncol 28:2174-80. 2010
    ....
  31. ncbi Increased HER2 gene copy number is associated with response to gefitinib therapy in epidermal growth factor receptor-positive non-small-cell lung cancer patients
    Federico Cappuzzo
    University of Colorado Cancer Center, Department of Medicine and Pathology, Aurora, CO 80010, USA
    J Clin Oncol 23:5007-18. 2005
    ..CONCLUSION: Increased copy number of the HER2 gene is associated with gefitinib sensitivity in EGFR-positive patients, supporting use of HER2 FISH analysis for selection of patients for TKI therapy...
  32. ncbi EGFR and HER2 genomic gain in recurrent non-small cell lung cancer after surgery: impact on outcome to treatment with gefitinib and association with EGFR and KRAS mutations in a Japanese cohort
    Marileila Varella-Garcia
    University of Colorado Cancer Center, Department of Medicine and Pathology, Aurora, CO 80045, USA
    J Thorac Oncol 4:318-25. 2009
    ..This study was carried out to verify whether EGFR FISH had similar performance in Japanese patients...
  33. ncbi Fluorescence versus white-light bronchoscopy for detection of preneoplastic lesions: a randomized study
    F R Hirsch
    Department of Pathology, University of Colorado Health Sciences Center and Cancer Center, Denver, USA
    J Natl Cancer Inst 93:1385-91. 2001
    ..17 to 1.65] versus DR for WLB = 0.67 [95% CI = 0.38 to 1.21]). CONCLUSION: LIFE was more sensitive than WLB in detecting preneoplastic bronchial changes in high-risk subjects. The prognostic implication of this finding is not yet clear...
  34. ncbi Early death during chemotherapy in patients with small-cell lung cancer: derivation of a prognostic index for toxic death and progression
    U N Lassen
    Finsen Center, Department of Oncology, Rigshospitalet, National University Hospital, Copenhagen, Denmark
    Br J Cancer 79:515-9. 1999
    ..We suggest that other groups evaluate our algorithm and exclude poor prognosis patients from trials of dose intensification...
  35. ncbi Chromosomal aneusomy in bronchial high-grade lesions is associated with invasive lung cancer
    Steinn Jonsson
    Department of Medicine Medical Oncology, University of Colorado Health Sciences Center, Campus Box 6511, Mail Box 8117, Aurora, CO 80045, USA
    Am J Respir Crit Care Med 177:342-7. 2008
    ..The development of lung cancer (LC) is accompanied by field changes in the airway mucosa that may have prognostic importance...
  36. ncbi Epidermal growth factor receptor messenger RNA expression, gene dosage, and gefitinib sensitivity in non-small cell lung cancer
    Rafal Dziadziuszko
    University of Colorado Health Sciences Center and University of Colorado Cancer Center, Aurora, Colorado 80045, USA
    Clin Cancer Res 12:3078-84. 2006
    ..EGFR gene dosage is neither predictive for response nor progression-free nor overall survival...
  37. ncbi Preclinical studies of gemcitabine and trastuzumab in breast and lung cancer cell lines
    Fred R Hirsch
    Department of Medicine, University of Colorado Cancer Center and the University of Colorado Health Sciences Center, Denver 80262, USA
    Clin Breast Cancer 3:12-6. 2002
    ..These preclinical studies indicate a need to study the clinical synergistic effects of the gemcitabine/trastuzumab combination in breast cancer and NSCLC patients whose tumors overexpress HER2/ neu...
  38. ncbi HER2/neu expression in malignant lung tumors
    Fred R Hirsch
    Lung Cancer Program, Department of Pathology, University of Colorado Cancer Center, Denver, CO 80262, USA
    Semin Oncol 29:51-8. 2002
    ..Future studies in NSCLC need to include immunohistochemistry and fluorescence in situ hybridization analysis to determine the method of choice for evaluating clinically relevant HER2/neu-positive tumors...
  39. ncbi Development of an integrated genomic classifier for a novel agent in colorectal cancer: approach to individualized therapy in early development
    Todd M Pitts
    Division of Medical Oncology, University of Colorado Denver, Aurora, CO 80045, USA
    Clin Cancer Res 16:3193-204. 2010
    ..The goal of this study was to develop and characterize predictive biomarkers for an IGFIR tyrosine kinase inhibitor, OSI-906, that could be applied in CRC-specific studies of this agent...
  40. ncbi Spectral karyotyping detects chromosome damage in bronchial cells of smokers and patients with cancer
    Marileila Varella Garcia
    Department of Medicine, School of Medicine, University of Colorado, Denver Health Sciences Center, Denver, Colorado, USA
    Am J Respir Crit Care Med 176:505-12. 2007
    ..Lung cancer is a multistep process that is preceded and often accompanied by molecular cytogenetic lesions in benign bronchial epithelium, the precise character, extent and timing of which are not well defined...
  41. ncbi Chromosomal abnormalities in non-small cell lung carcinomas and in bronchial epithelia of high-risk smokers detected by multi-target interphase fluorescence in situ hybridization
    Maura Santos Romeo
    Department of Medicine, School of Medicine, University of Colorado Health Sciences Center, Denver, Colorado 80262, USA
    J Mol Diagn 5:103-12. 2003
    ..Chromosomal aneusomy is also frequent in bronchial epithelial cells from long-term smokers. The prognostic significance of the multicolor LAVysion FISH probe set should be validated in a controlled clinical trial...
  42. ncbi A dose escalating study of topotecan preceding cisplatin in previously untreated patients with small-cell lung cancer
    M Sorensen
    The Finsen Centre, Rigshospitalet, Copenhagen, Denmark
    Ann Oncol 11:829-35. 2000
    ..The aim was to define the MTD of topotecan (TPT) given before cisplatin in patients with previously untreated SCLC...
  43. ncbi High-throughput tissue microarray analysis used to evaluate biology and prognostic significance of the E-cadherin pathway in non-small-cell lung cancer
    R M Bremnes
    Department of Pathology, Division of Medical Oncology, University of Colorado Cancer Center, Denver, CO, USA
    J Clin Oncol 20:2417-28. 2002
    ..We constructed tissue microarrays (TMAs) to investigate the expression of cadherins and catenins and their prognostic significance in NSCLC...
  44. ncbi Are pathologists biased by clinical information?: A blinded cross-over study of the histopathological diagnosis of mesothelial tumours versus pulmonary adenocarcinoma
    B G Skov
    Department of Pathology, Frederiksberg Hospital, Denmark
    Lung Cancer 11:365-72. 1994
    ..The reproducibility also improved significantly when these slides were available...
  45. ncbi Epidermal growth factor receptor family in lung cancer and premalignancy
    Wilbur A Franklin
    Department of Pathology, University of Colorado Health Sciences Center, Denver, CO 80262, USA
    Semin Oncol 29:3-14. 2002
    ..These trials represent a new targeted approach to lung cancer treatment and chemoprevention that will require greater attention to molecular endpoints than required in past trials...
  46. ncbi Combined use of oligonucleotide and tissue microarrays identifies cancer/testis antigens as biomarkers in lung carcinoma
    Michio Sugita
    Department of Pathology, University of Colorado Health Sciences Center, Denver, Colorado 80262, USA
    Cancer Res 62:3971-9. 2002
    ....
  47. ncbi Selecting lung cancer patients for treatment with epidermal growth factor receptor tyrosine kinase inhibitors by immunohistochemistry and fluorescence in situ hybridization--why, when, and how?
    Rafal Dziadziuszko
    University of Colorado Health Sciences Center, Aurora 80045, USA
    Clin Cancer Res 12:4409s-4415s. 2006
    ..Expeditious validation of this information in prospective clinical trials with patient selection to first-line treatment is currently being done or planned by several cancer research groups worldwide...
  48. ncbi Sputum cytological atypia as a predictor of incident lung cancer in a cohort of heavy smokers with airflow obstruction
    Sheila A Prindiville
    Department of Medicine, School of Medicine, University of Colorado Health Sciences Center, Denver, Colorado 80262, USA
    Cancer Epidemiol Biomarkers Prev 12:987-93. 2003
    ....
  49. ncbi Monoclonal antibodies in the detection of bone marrow metastases in small cell lung cancer
    B G Skov
    Department of Pathology, Rigshospitalet, Copenhagen, Denmark
    Br J Cancer 65:593-6. 1992
    ..However, these antibodies could not detect metastatic tumour cells in the bone marrow sections from patients in whom CE did not reveal any tumour cells...
  50. ncbi The detection of chromosomal aneusomy by fluorescence in situ hybridization in sputum predicts lung cancer incidence
    Marileila Varella-Garcia
    University of Colorado Denver, 12801 East 17th Avenue, Aurora, CO 80045, USA
    Cancer Prev Res (Phila) 3:447-53. 2010
    ..The apparent promise of CA-FISH in sputum for assessing lung cancer risk and/or for lung cancer early detection now needs to be validated in a clinical screening trial...
  51. ncbi KRAS mutations and sensitivity to epidermal growth factor receptor inhibitors in colorectal cancer: practical application of patient selection
    Antonio Jimeno
    Medical Oncology Division, PO Box 6511, MS 8117, Aurora, CO, 80045, USA
    J Clin Oncol 27:1130-6. 2009
    ....
  52. ncbi High prevalence of occult endobronchial malignancy in high risk patients with moderate sputum atypia
    Timothy C Kennedy
    University of Colorado Comprehensive Cancer Center, University of Colorado Health Sciences Center, Denver, CO, USA
    Lung Cancer 49:187-91. 2005
    ..Seven additional subjects had severe dysplasia found on endobronchial biopsy. Moderate sputum atypia may be an important marker of risk for occult endobronchial malignancy in high risk subjects...
  53. ncbi The role of HER2/neu expression and trastuzumab in non-small cell lung cancer
    Fred R Hirsch
    University of Colorado Cancer Center, Department of Medical Oncology/Pathology, Denver 80262, USA
    Semin Oncol 31:75-82. 2004
    ..However, to date, clinical studies with trastuzumab in patients with NSCLC have not shown a demonstrable advantage for the majority of patients...
  54. ncbi Review of recent advances in fluorescence bronchoscopy in early localization of central airway lung cancer
    T C Kennedy
    Division of Pulmonary and Critical Care, University of Colorado Health Science Center, Denver, CO 80218, USA
    Oncologist 6:257-62. 2001
    ....
  55. ncbi [Lung cancer screening--what now?]
    R M Bremnes
    Kreftavdelingen, Regionsykehuset i Tromsø 9038 Tromsø
    Tidsskr Nor Laegeforen 121:1600-4. 2001
    ..Over the course of the last decade, rapid advances in molecular biology, pathology, bronchoscopy and radiology have provided a rational basis for earlier diagnosis and improved outcome...
  56. ncbi Restoring E-cadherin expression increases sensitivity to epidermal growth factor receptor inhibitors in lung cancer cell lines
    Samir E Witta
    Department of Medicine Medical Oncology, University of Colorado Health Sciences Center and University of Colorado Cancer Center, Campus Box 8117, PO Box 6511, Aurora, CO 80045, USA
    Cancer Res 66:944-50. 2006
    ..Thus, combined HDAC inhibitor and gefitinib treatment represents a novel pharmacologic strategy for overcoming resistance to EGFR inhibitors in patients with lung cancer...
  57. ncbi Lack of association between sputum atypia and chronic obstructive pulmonary disease mortality
    York E Miller
    Denver Veterans Affairs Medical Center, Denver, Colorado 80220 3808, USA
    J Thorac Oncol 1:302-7. 2006
    ..The authors hypothesized that sputum atypia would reflect the processes leading to progressive airflow obstruction and might be a novel biomarker of more rapidly progressive COPD...
  58. ncbi The bronchioloalveolar carcinoma and peripheral adenocarcinoma spectrum of diseases
    David H Garfield
    Department of Medicine, University of Colorado Health Sciences Center, Aurora, Colorado 80010, USA
    J Thorac Oncol 1:344-59. 2006
    ..Because of frequent lung-only recurrences, lung transplantation, although performed rarely, may hold promise...
  59. ncbi KRAS mutations and susceptibility to cetuximab and panitumumab in colorectal cancer
    Antonio Jimeno
    University of Colorado Cancer Center, Denver, CO, USA
    Cancer J 15:110-3. 2009
    ..In this article, we will review the available clinical data and discuss the implications for future drug development in colorectal cancer...
  60. ncbi Unusual chemosensitivity of advanced bronchioalveolar carcinoma after gefitinib response and progression: a case report
    Rafal Dziadziuszko
    Department of Medical Oncology, University of Colorado Cancer Center, Aurora, CO 80045, USA
    J Thorac Oncol 2:91-2. 2007
    ..Molecular characterization of the primary tumor before any treatment is provided, and mechanisms of resistance to epidermal growth factor receptor tyrosine kinase inhibitors are briefly discussed...
  61. ncbi Analysis of orthologous gene expression between human pulmonary adenocarcinoma and a carcinogen-induced murine model
    Robert S Stearman
    Department of Medicine Pulmonary Sciences and Critical Care Medicine, University of Colorado Health Sciences Center, Denver, USA
    Am J Pathol 167:1763-75. 2005
    ..Thus, the A/J mouse-urethane model reflects significant molecular details of human lung AC, and comparison of changes in orthologous gene expression may provide novel insights into lung carcinogenesis...
  62. ncbi Sputum cytologic atypia predicts incident lung cancer: defining latency and histologic specificity
    Tim Byers
    School of Medicine, University of Colorado Comprehensive Cancer Center, 13001 East 17th Place, Aurora, CO 80045, USA
    Cancer Epidemiol Biomarkers Prev 17:158-62. 2008
    ..Radiologic imaging may be more sensitive for peripheral cancers than for cancers arising in the central airways, from which bronchial epithelial cells are exfoliated into the sputum...
  63. ncbi The rationale and development of therapeutic insulin-like growth factor axis inhibition for lung and other cancers
    D Ross Camidge
    Developmental Therapeutics Program, University of Colorado Cancer Center, Denver Thoracic Oncology Program, University of Colorado Cancer Center, Denver, Colorado 80045, USA
    Clin Lung Cancer 10:262-72. 2009
    ..Explorations of aspects of ligands, binding proteins, receptors, and receptor substrates are all ongoing to identify potential biomarkers predictive of benefit from IGF axis intervention...
  64. ncbi Bronchial epithelial Ki-67 index is related to histology, smoking, and gender, but not lung cancer or chronic obstructive pulmonary disease
    York E Miller
    Division of Pulmonary Sciences and Critical Care Medicine, Department of Medicine, Denver Veterans Affairs Medical Center, University of Colorado at Denver, Denver, Colorado 80220, USA
    Cancer Epidemiol Biomarkers Prev 16:2425-31. 2007
    ..To determine whether increased bronchial epithelial proliferation is associated with histology, smoking status, gender, age, chronic obstructive pulmonary disease (COPD), or lung cancer...
  65. ncbi Multi-target interphase fluorescence in situ hybridization assay increases sensitivity of sputum cytology as a predictor of lung cancer
    Marileila Varella-Garcia
    Department of Medicine, School of Medicine, University of Colorado Health Sciences Center, Cancer Center, Campus Box B188, Denver 80262, USA
    Cancer Detect Prev 28:244-51. 2004
    ..Combining both tests, abnormality was found in 83% of the cases and 20% of the controls (P = 0.0004) suggesting that FISH may improve the sensitivity of cytologic atypia as a predictor of lung cancer...
  66. ncbi Baseline gene expression predicts sensitivity to gefitinib in non-small cell lung cancer cell lines
    Christopher D Coldren
    Division of Pulmonary Sciences and Critical Care Medicine, University of Colorado Health Sciences Center, 4200 East Ninth Avenue, C272, Denver, 80262, USA
    Mol Cancer Res 4:521-8. 2006
    ..Some of these genes could be targets of pharmacologic interventions to overcome primary resistance...
  67. ncbi Biological markers for non-small cell lung cancer patient selection for epidermal growth factor receptor tyrosine kinase inhibitor therapy
    Paul A Bunn
    Department of Medicine, University of Colorado Cancer Center and University of Colorado Health Sciences Center, Aurora, 80045, USA
    Clin Cancer Res 12:3652-6. 2006
  68. ncbi A randomized phase II chemoprevention trial of 13-CIS retinoic acid with or without alpha tocopherol or observation in subjects at high risk for lung cancer
    Karen Kelly
    Pulmonary 111A, Denver VA Medical Center, 1055 Clermont Street, Denver, CO 80220, USA
    Cancer Prev Res (Phila) 2:440-9. 2009
    ..Agents advancing to phase III randomized trials should produce greater histologic changes. The addition of alpha tocopherol did not affect toxicity...
  69. ncbi High prevalence of endobronchial malignancy in high-risk patients with moderate dysplasia in sputum
    Timothy C Kennedy
    Specialized Program of Research Excellence (SPORE) in Lung Cancer, University of Colorado Cancer Center, Denver, CO 80218, USA
    Chest 125:109S. 2004
  70. ncbi Early detection and screening of lung cancer
    Celine Mascaux
    University of Colorado Denver, Anschutz Medical Campus, 12801 East 17th Avenue, Aurora, CO 80045, USA
    Expert Rev Mol Diagn 10:799-815. 2010
    ..These include imaging techniques, bronchoscopies, molecular screenings from different noninvasive or invasive sources, such as blood, sputum, bronchoscopic samples and exhaled breath...
  71. ncbi Expression of target molecules in lung cancer: challenge for a new treatment paradigm
    Fred R Hirsch
    University of Colorado Cancer Center and Department of Medicine, University of Colorado Health Sciences Center, Denver, CO 80262, USA
    Semin Oncol 29:2-8. 2002
    ....
  72. ncbi Using molecular markers in sputum for the early detection of lung cancer: a review
    Timothy C Kennedy
    University of Colorado Cancer Center, Specialized Program of Research Excellence, National Cancer Institute, 4200 E 9th Ave, Denver, CO 80262, USA
    Lung Cancer 45:S21-7. 2004
    ....
  73. ncbi The E-cadherin cell-cell adhesion complex and lung cancer invasion, metastasis, and prognosis
    Roy M Bremnes
    Department of Pathology, University of Colorado Cancer Center, Denver, USA
    Lung Cancer 36:115-24. 2002
    ..Reduced expression of this complex in malignant disease is associated with tumour invasion, metastasis, and unfavorable prognosis...
  74. ncbi Recent developments in biomarkers for the early detection of lung cancer: perspectives based on publications 2003 to present
    Thomas D Chanin
    University of Colorado Health Sciences Center, Department of Pathology and University of Colorado Cancer Center, Denver, Colorado 80262, USA
    Curr Opin Pulm Med 10:242-7. 2004
    ....
  75. ncbi Targeted molecular mechanisms of epoetin alfa
    Corey J Langer
    Department of Medical Oncology, Fox Chase Cancer Center, 7701 Burholme Avenue, Philadelphia, PA 19111, USA
    Lung Cancer 41:S133-45. 2003
    ..Future research needs to be conducted to explore the potential for epoetin alfa to improve survival time in lung cancer patients...
  76. ncbi The tissue is the issue: personalized medicine for non-small cell lung cancer
    Fred R Hirsch
    University of Colorado Cancer Center, Aurora, Colorado 80045, USA
    Clin Cancer Res 16:4909-11. 2010
    ..Different molecular assays, validation, and clinical application to different types of tissue specimens are discussed...
  77. ncbi Targeting anemia in patients with lung cancer
    Jeffrey Crawford
    Division of Medical Oncology, Duke University Medical Center, Durham, North Carolina 27710, USA
    J Thorac Oncol 1:716-25. 2006
    ....
  78. ncbi EGFR: a prognostic and/or a predictive marker?
    Fred R Hirsch
    J Thorac Oncol 1:395-7. 2006
  79. ncbi Epidermal growth factor receptor inhibitors plus chemotherapy in non-small-cell lung cancer: biologic rationale for combination strategies
    David R Gandara
    University of California Davis Cancer Center, Sacramento, CA 95817, USA
    Clin Lung Cancer 8:S61-7. 2007
    ....
  80. ncbi Bronchioloalveolar carcinoma: a model for investigating the biology of epidermal growth factor receptor inhibition
    David R Gandara
    University of California Davis Cancer Center, Sacramento, California, USA
    Clin Cancer Res 10:4205s-4209s. 2004
    ..These studies provide a biological rationale for investigating BAC as a model of predictive markers of EGFR inhibition...
  81. ncbi The biology of epidermal growth factor receptor in lung cancer
    Giorgio V Scagliotti
    Department of Clinical and Biological Sciences, S Luigi Gonzaga, University of Torino, Thoracic Oncology Unit, Torino, Italy
    Clin Cancer Res 10:4227s-4232s. 2004
    ..New technologies such as nucleotide arrays and proteomics will help to elucidate the issue by providing information on how EGFR signaling may affect the expression of genes and proteins in cancer cells...
  82. ncbi Increased epidermal growth factor receptor gene copy number is associated with poor prognosis in head and neck squamous cell carcinomas
    Christine H Chung
    Division of Hematology Oncology, Department of Medicine, Vanderbilt Ingram Comprehensive Cancer Center, Vanderbilt University School of Medicine, Nashville, TN 37232 6307, USA
    J Clin Oncol 24:4170-6. 2006
    ..A better understanding of the EGFR pathway may improve the use of EGFR inhibitors in HNSCC...
  83. ncbi K-ras mutations in lung cancer: the "mysterious mutation"
    Fred R Hirsch
    Clin Lung Cancer 8:11-2. 2006
  84. ncbi Systemic therapy of advanced bronchioloalveolar cell carcinoma: challenges and opportunities
    Vincent A Miller
    Thoracic Oncology Service, Memorial Sloan Kettering Cancer Center, Room 1012 H Building, 1275 York Avenue, New York, NY 10021, USA
    J Clin Oncol 23:3288-93. 2005
    ....
  85. ncbi Epidermal growth factor receptor inhibitors in lung cancer: smaller or larger molecules, selected or unselected populations?
    Fred R Hirsch
    J Clin Oncol 23:9044-7. 2005
  86. ncbi Promoter hypermethylation of multiple genes in sputum precedes lung cancer incidence in a high-risk cohort
    Steven A Belinsky
    Lung Cancer Program, Lovelace Respiratory Research Institute, Albuquerque, New Mexico 87108, USA
    Cancer Res 66:3338-44. 2006
    ....
  87. ncbi EGFR and HER2 gene copy number and response to first-line chemotherapy in patients with advanced non-small cell lung cancer (NSCLC)
    Federico Cappuzzo
    Department of Hematology Oncology, Istituto Clinico Humanitas, Rozzano, Italy
    J Thorac Oncol 2:423-9. 2007
    ..The aim of this study was to assess whether EGFR and HER2 gene copy number and Akt activation are associated with response to first-line chemotherapy...
  88. ncbi Lung cancer screening by spiral CT. What is the optimal target population for screening trials?
    Rob J van Klaveren
    Department of Pulmonology, Erasmus Medical Centre, University Hospital Rotterdam, Dr Molewaterplein 40, 3015 GD Rotterdam, The Netherlands
    Lung Cancer 38:243-52. 2002
    ..The inadequacy of the unit 'Pack-Years' (PY) to estimate the individual lung cancer risk is recognised, and future initiatives to develop an appropriate lung cancer risk model are encouraged...
  89. ncbi Mass spectrometry to classify non-small-cell lung cancer patients for clinical outcome after treatment with epidermal growth factor receptor tyrosine kinase inhibitors: a multicohort cross-institutional study
    Fumiko Taguchi
    Department of Medicine, Vanderbilt Ingram Cancer Center, Nashville, TN 37232 6838, USA
    J Natl Cancer Inst 99:838-46. 2007
    ....
  90. ncbi Chemoprevention of lung cancer: current status and future prospects
    Nico van Zandwijk
    Department of Thoracic Oncology, Netherlands Cancer Institute, Plesmanlaan 121, 1066 CX Amsterdam, The Netherlands
    Lung Cancer 42:S71-9. 2003
    ..This article reviews the lung cancer chemoprevention efforts of the last two decades and also gives prospects for the next coming years...
  91. ncbi Coordinated epidermal growth factor receptor pathway gene overexpression predicts epidermal growth factor receptor inhibitor sensitivity in pancreatic cancer
    Antonio Jimeno
    Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins University, Baltimore, MD 21231 1000, USA
    Cancer Res 68:2841-9. 2008
    ..These results suggest a phenomenon of pathway addiction and support the value of unbiased system biology approaches in drug development...
  92. ncbi Advances in genomic and proteomic studies of non-small-cell lung cancer: clinical and translational research perspective
    Rafal Dziadziuszko
    Department of Oncology and Radiotherapy, Medical University of Gdansk, Poland
    Clin Lung Cancer 9:78-84. 2008
    ..These markers should be prospectively tested in clinical studies before they can be routinely used in the clinic...
  93. ncbi Summary statement novel agents in the treatment of lung cancer: Fifth Cambridge Conference assessing opportunities for combination therapy
    Thomas J Lynch
    Massachusetts General Hospital Cancer Center, Boston, Massachusetts 02114, USA
    J Thorac Oncol 3:S107-12. 2008
    ..A CME activity based on this summary is also available at www.informedicalcme.com/cme...
  94. ncbi Lung cancer chemoprevention: moving from concept to a reality
    James L Mulshine
    Intervention Section, Cell and Cancer Biology Branch, Center for Cancer Research, National Cancer Institute, National Institutes for Health, Bethesda, MD 20892 1906, USA
    Lung Cancer 41:S163-74. 2003
    ..The paper describes approaches to tailor chemoprevention development specifically to the biological, pharmacological and anatomical realities of this most lethal cancer...
  95. ncbi EGFR inhibitors in the treatment of lung cancer
    Fred R Hirsch
    Onkologie 30:476. 2007
  96. ncbi Gefitinib versus vinorelbine in chemotherapy-naive elderly patients with advanced non-small-cell lung cancer (INVITE): a randomized, phase II study
    Lucio Crino
    Department of Medical Oncology, Perugia Hospital, S Andrea delle Fratte, 06156 Perugia, Italy
    J Clin Oncol 26:4253-60. 2008
    ..This phase II, open-label, parallel-group study compared gefitinib with vinorelbine in chemotherapy-naïve elderly patients with advanced non-small-cell lung cancer (NSCLC)...
  97. ncbi Lung cancer. Introduction
    Fred R Hirsch
    Lung Cancer 41:S1. 2003
  98. ncbi Tobacco money: up in smoke?
    James L Mulshine
    Lancet 360:1979-80; author reply 1981. 2002
  99. ncbi What is the role of HER-2/neu and trastuzumab (Herceptin) in lung cancer?
    Fred R Hirsch
    Lung Cancer 36:263-4. 2002